Developer docs
API playgroundTry for free, no card

Search company profiles

Pico IV

Full company profile

uuid0008syk

Namestring
Pico IV
Legal namestring
Pico IV Inc.
Websiteurl
picoiv.com
Company typeenum
Private
Founded yearint
2023
Descriptiontext

Pico IV, Inc. is a Sacramento, California-based privately held company founded in 2023 that develops and sells the world's first sterile CBD intravenous (IV) solution, protected by US Patent #12,569,504. Its core technology is a proprietary pico-emulsion process that reduces CBD particle size to the picometer scale (claimed to be 1,000x smaller than nanoemulsions), enabling CBD to become water-soluble and pass through sterile filtration, a previously unsolved constraint for IV-delivered cannabinoids. Products are manufactured in a cGMP facility using e-beam sterilization and are tested at ISO-accredited third-party labs (KCA Labs, California Ag Labs), with Certificates of Analysis published for each batch.

The product portfolio includes sterile CBD Broad Spectrum vials in 5ml, 10ml, 20ml, and 50ml formats and a Core-A formulation featuring acidic cannabinoids (CBD-A and CBG-A). The company serves licensed medical clinics, functional and regenerative medicine practices, and national IV therapy franchise networks (DRIPBaR with 120+ locations, iCRYO with 50 US/Canada locations, and Liquivida). Distribution runs through a HIPAA-compliant B2B provider portal (with training, ordering, and recurring 20%-discount subscriptions) and a small direct-to-consumer e-commerce channel; the website ships only within the United States. Revenue is generated via per-vial product sales and provider subscriptions, with per-unit pricing not publicly disclosed.

Operationally, Pico IV has built a footprint of 200+ clinics across nearly all 50 US states and has been expanding into clinical and specialty applications through collaborations such as a January 2026 neurologist-guided protocol with BrainThrive, PC. The company is founder-owned and operated, with no disclosed external venture funding, no parent company, and no subsidiaries. Its leadership engagement includes Liquivida founder Sam Tejada joining its Advisory Board as a spokesperson, and clinical data infrastructure is being built on AdvancedMD and REDcap Cloud integrations to document patient-reported outcomes.

Short descriptiontext

Pico IV is a Sacramento-based private company that develops and sells the world's first sterile CBD IV solution, using patented pico-emulsion technology to make CBD water-soluble and filterable, sold to licensed clinics and IV therapy franchise networks through a HIPAA-compliant provider portal.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSacramento, United States
HQ citystring
Sacramento
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
sterile CBD IV solutions, pico-emulsion technology, cannabidiol IV formulations, pharmaceutical-grade CBD products, IV therapy supplies
Industry3 codes
PRIMARYHLAFALAE
Compounding Pharmacies (Sterile/Non-Sterile)
Healthcare & Life Sciences/Healthcare Providers & Systems/Pharmacy & Medication Management Services
SECONDARYCRAOAIAG
Hemp & CBD Product Wholesale Distribution
Consumer Products & Retail/Wholesale, Distribution & Category Management/Alcohol, Tobacco & Cannabis Wholesale Distribution
SECONDARYCRANAHAC
CBD/Hemp Wellness & Supplements Retail
Consumer Products & Retail/Tobacco, Alcohol & Cannabis Retail/Cannabis Specialty Retail (CBD/Hemp & Accessories)
NAICS code1 code
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Sterile CBD IV Pharmaceutical Products
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Sterile CBD IV Product Sales
TypeSubscription Recurring
Description

Pico IV sells its sterile CBD solution vials directly to healthcare providers and clinics through a B2B provider portal and e-commerce platform. Providers purchase products for administration in clinical settings. The company offers subscribe-and-save options for recurring purchases.

picoiv.com
2B2B Provider Portal
TypeOne Time License
Description

Healthcare providers register through a HIPAA-compliant provider portal to access products, training resources, ordering system, and clinical information. The portal facilitates efficient inventory management and reordering.

picoiv.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Supply Chain, Operations, Technology or R&D, Personnel, Marketing or Sales
Pricing details1 tier
1Standard Retail Products
ModelUnit PricingBilling cadenceMonthly
Notes

Products available in various volumes: 5ml, 10ml, 20ml, 50ml vials. CBD Broad Spectrum options include 200mg (50ml), 66mg (10ml), and 29mg (5.8ml Core-A) variants. Subscription and save option offers 20% discount.

picoiv.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Pico IV develops, manufactures, and distributes the world's first sterile CBD IV solution using proprietary pico-emulsion technology that reduces CBD particles to picometer scale (1000x smaller than nanoemulsions), enabling water solubility and passage through sterile filtration for true IV-administerable CBD. The company sells sterile CBD Broad Spectrum Vials (in 5ml, 10ml, 20ml, and 50ml sizes) and a Core-A acidic cannabinoid formulation to licensed medical clinics, wellness franchises, and consumers through a HIPAA-compliant B2B Provider Portal and DTC e-commerce.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Available in over 200 clinics across almost all 50 states
+1 more record
Product overview1 text field

Pico IV is a B2B wellness technology company that developed and manufactures the world's first sterile CBD IV solution, protected by US Patent #12,569,504. The company's core offering consists of proprietary pico emulsion technology that reduces CBD particles to picometer scale (1000x smaller than nanoemulsions), enabling water solubility and true sterile filtration for IV administration. The product portfolio includes CBD Broad Spectrum Vials (available in 5ml, 10ml, 20ml, and 50ml sizes with varying potencies) and Core-A formulations featuring acidic cannabinoids (CBD-A and CBG-A). All products undergo rigorous third-party testing at ISO-accredited labs (KCA Labs, California Ag Labs) with published Certificates of Analysis. The company operates exclusively through licensed medical clinics via a HIPAA-compliant Provider Portal that offers ordering systems, clinical training, and support resources. Pico IV's products are currently available in over 200 clinics across nearly all 50 US states.

Product and service5 records
1PICO IV Sterile CBD IV Solution
CategorySterile CBD IV Pharmaceutical Products
Description

World's first and only sterile CBD IV solution, utilizing proprietary pico-emulsion technology that reduces CBD particles to picometer scale for water solubility and sterile filtration, enabling direct IV administration of CBD for enhanced bioavailability. Sold to licensed medical clinics and wellness providers for in-clinic IV administration.

2PICO IV CBD Broad Spectrum Vial
CategorySterile CBD IV Pharmaceutical Products
Description

Sterile CBD IV solution available in 5ml, 10ml, 20ml, and 50ml vials with varying CBD concentrations (approximately 6.4 mg/mL potency). Contains multiple cannabinoids including CBD, CBG, CBGa, CBDa, CBC, and CBN. Third-party lab tested for pesticides, microbials, mycotoxins, heavy metals, and residual solvents.

3PICO IV Core-A
CategorySterile CBD IV Pharmaceutical Products
Description

Specialized CBD IV formulation featuring CBD-A and CBG-A acidic cannabinoids at 0.161 mg/mL potency in 5.8ml vials. Third-party lab tested for purity and potency.

4PICO IV Provider Portal
CategoryB2B Healthcare Platform
Description

HIPAA-compliant B2B platform providing licensed medical clinics access to ordering, inventory management, clinical resources, training materials, and Certificate of Analysis documentation. Includes 1-on-1 training, FAQs, forum groups, and downloads. Required applicants to be licensed medical clinics.

5PICO IV Subscriptions (Subscribe & Save)
CategorySubscription / Recurring Fulfillment
Description

Recurring subscription program offering 20% savings on repeat orders of PICO IV sterile CBD IV vials for registered clinic and consumer members via the picoiv.com storefront.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
1BrainThrive, PC
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-13
Description

Clinical collaboration to deliver patented sterile CBD solution at BrainThrive's Westlake Village neurology clinic. Creates a neurologist-guided protocol for CBD IV therapy with structured delivery and real-world clinical measurement using AdvancedMD to document patient-reported outcomes alongside neurological indicators. Aligned with December 19 Executive Order on medical marijuana and CBD research priorities.

prnewswire.com
2The DRIPBaR
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-11-04
Description

Strategic partnership to expand access to sterile CBD solutions nationwide through DRIPBaR's franchise locations. The partnership aims to improve wellness support through IV therapy and CBD products, leveraging both companies' reputations and safety standards. Products accessible via franchise's more than 120 locations.

einpresswire.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-09-17
Description

Partnership to bring first sterile CBD emulsion to mainstream wellness protocols. Liquivida founder Sam Tejada joins PICO IV's Advisory Board as official spokesperson while continuing as Chairman of Leadership Advisory Board for American IV Association. Companies plan to educate providers and patients on endocannabinoid system and integrate pharmaceutical-grade CBD (manufactured in cGMP facility using e-beam sterilization) into customized wellness and performance protocols.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-02-05
Description

Partnership to accelerate availability of CBD IV infusions through iCRYO's national wellness provider network. Pico IV's first-of-its-kind CBD IV therapy (launched August 2023) made available through iCRYO's 50 franchise locations across US and Canada, aiming to accelerate CBD acceptance into mainstream wellness services.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

CBD brand focused on tinctures, capsules, topicals, and sleep/recovery products, including partnerships with healthcare professionals. Comparable positioning as a science-forward, professionally distributed CBD brand targeting practitioner channels.

TypeDirect peer
Description

Large-scale CBD brand under Balanced Health Botanicals offering tinctures, gummies, capsules, and topicals with strong value positioning. Comparable as a high-volume CBD brand competing for the same practitioner and consumer audience.

TypeDirect peer
Description

Global CBD brand (formerly Elixinol Global) producing tinctures, capsules, topicals, and skincare. Comparable as a science-positioned CBD consumer brand with international distribution ambitions.

4Receptra Naturals
TypeDirect peer
Description

CBD brand focused on recovery, sleep, and active-lifestyle SKUs, with professional/athlete channels. Comparable as a specialty CBD brand targeting wellness, recovery, and practitioner-oriented distribution.

5Trokie
TypeEmerging player
Description

Smaller CBD pharma-adjacent brand focused on buccal/sublingual CBD delivery with a clinical/pharmacy distribution angle. Comparable as an emerging, clinically-positioned CBD player with a differentiated delivery format similar in spirit to Pico IV's novel IV route.

TypeBroad incumbent
Description

One of the largest and most established CBD wellness brands in the US, selling tinctures, gummies, capsules, and topicals across retail and DTC channels. Comparable as a premium CBD consumer brand, though it lacks Pico IV's sterile IV formulation and B2B clinic channel.

TypeDirect peer
Description

Public CBD brand selling tinctures, gummies, topicals, and sleep/recovery products with national retail and DTC reach. Comparable as a multi-format, mass-distributed CBD brand competing for the same wellness-conscious consumer.

TypeBroad incumbent
Description

Public CBD company (PlusCBD Oil brand) producing CBD extracts, capsules, topicals, and pet products. Comparable as a regulated, quality-focused CBD manufacturer operating in similar wellness and practitioner channels.

TypeDirect peer
Description

Vertically integrated CBD brand offering tinctures, capsules, topicals, and pet products with a strong value and accessibility positioning. Comparable as a multi-format CBD consumer brand with significant scale and broad distribution.

TypeDirect peer
Description

National franchise chain offering IV therapy, cryotherapy, infrared, and wellness services — closely matching Pico IV's IV therapy clinic channel. Comparable as a distributed IV therapy operator that could similarly partner with or compete for sterile CBD IV suppliers.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration4 records

Each record includes

Title, Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Pico IV

Sterile CBD IV Pharmaceutical Productspicoiv.com

Pico IV is a Sacramento-based private company that develops and sells the world's first sterile CBD IV solution, using patented pico-emulsion technology to make CBD water-soluble and filterable, sold to licensed clinics and IV therapy franchise networks through a HIPAA-compliant provider portal.

What Pico IV does

Pico IV, Inc. is a Sacramento, California-based privately held company founded in 2023 that develops and sells the world's first sterile CBD intravenous (IV) solution, protected by US Patent #12,569,504. Its core technology is a proprietary pico-emulsion process that reduces CBD particle size to the picometer scale (claimed to be 1,000x smaller than nanoemulsions), enabling CBD to become water-soluble and pass through sterile filtration, a previously unsolved constraint for IV-delivered cannabinoids. Products are manufactured in a cGMP facility using e-beam sterilization and are tested at ISO-accredited third-party labs (KCA Labs, California Ag Labs), with Certificates of Analysis published for each batch.

The product portfolio includes sterile CBD Broad Spectrum vials in 5ml, 10ml, 20ml, and 50ml formats and a Core-A formulation featuring acidic cannabinoids (CBD-A and CBG-A). The company serves licensed medical clinics, functional and regenerative medicine practices, and national IV therapy franchise networks (DRIPBaR with 120+ locations, iCRYO with 50 US/Canada locations, and Liquivida). Distribution runs through a HIPAA-compliant B2B provider portal (with training, ordering, and recurring 20%-discount subscriptions) and a small direct-to-consumer e-commerce channel; the website ships only within the United States. Revenue is generated via per-vial product sales and provider subscriptions, with per-unit pricing not publicly disclosed.

Operationally, Pico IV has built a footprint of 200+ clinics across nearly all 50 US states and has been expanding into clinical and specialty applications through collaborations such as a January 2026 neurologist-guided protocol with BrainThrive, PC. The company is founder-owned and operated, with no disclosed external venture funding, no parent company, and no subsidiaries. Its leadership engagement includes Liquivida founder Sam Tejada joining its Advisory Board as a spokesperson, and clinical data infrastructure is being built on AdvancedMD and REDcap Cloud integrations to document patient-reported outcomes.

Pico IV firmographics

Firmographics
Name
Pico IV
Legal name
Pico IV Inc.
Website
https://picoiv.com
Company type
Private
Founded year
2023
Operating status
Operating
Headcount range
11–50 employees
Short description
Pico IV is a Sacramento-based private company that develops and sells the world's first sterile CBD IV solution, using patented pico-emulsion technology to make CBD water-soluble and filterable, sold to licensed clinics and IV therapy franchise networks through a HIPAA-compliant provider portal.
Ownership category
akta.pro rank

Pico IV industry classification

Industry
Product category
Sterile CBD IV Pharmaceutical Products
NAICS
Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAFALAE
Compounding Pharmacies (Sterile/Non-Sterile)
Healthcare & Life Sciences/Healthcare Providers & Systems/Pharmacy & Medication Management Services
SECONDARYCRAOAIAG
Hemp & CBD Product Wholesale Distribution
Consumer Products & Retail/Wholesale, Distribution & Category Management/Alcohol, Tobacco & Cannabis Wholesale Distribution
SECONDARYCRANAHAC
CBD/Hemp Wellness & Supplements Retail
Consumer Products & Retail/Tobacco, Alcohol & Cannabis Retail/Cannabis Specialty Retail (CBD/Hemp & Accessories)

Keywords

  • Sterile CBD IV solutions
  • Pico-emulsion technology
  • Cannabidiol IV formulations
  • Pharmaceutical-grade CBD products
  • IV therapy supplies

Where Pico IV is headquartered

Location

Headquarters

HQ city
Sacramento
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Pico IV business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Operations, Technology or R&D, Personnel, Marketing or Sales

Revenue model

  1. Sterile CBD IV Product Sales: Pico IV sells its sterile CBD solution vials directly to healthcare providers and clinics through a B2B provider portal and e-commerce platform. Providers purchase products for administration in clinical settings. The company offers subscribe-and-save options for recurring purchases.
  2. B2B Provider Portal: Healthcare providers register through a HIPAA-compliant provider portal to access products, training resources, ordering system, and clinical information. The portal facilitates efficient inventory management and reordering.

Pricing tiers

ModelBillingPrice
Unit PricingMonthlyStandard Retail Products

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Pico IV product offering

Product offering

Core offering

Pico IV develops, manufactures, and distributes the world's first sterile CBD IV solution using proprietary pico-emulsion technology that reduces CBD particles to picometer scale (1000x smaller than nanoemulsions), enabling water solubility and passage through sterile filtration for true IV-administerable CBD. The company sells sterile CBD Broad Spectrum Vials (in 5ml, 10ml, 20ml, and 50ml sizes) and a Core-A acidic cannabinoid formulation to licensed medical clinics, wellness franchises, and consumers through a HIPAA-compliant B2B Provider Portal and DTC e-commerce.

Product overview

Pico IV is a B2B wellness technology company that developed and manufactures the world's first sterile CBD IV solution, protected by US Patent #12,569,504. The company's core offering consists of proprietary pico emulsion technology that reduces CBD particles to picometer scale (1000x smaller than nanoemulsions), enabling water solubility and true sterile filtration for IV administration. The product portfolio includes CBD Broad Spectrum Vials (available in 5ml, 10ml, 20ml, and 50ml sizes with varying potencies) and Core-A formulations featuring acidic cannabinoids (CBD-A and CBG-A). All products undergo rigorous third-party testing at ISO-accredited labs (KCA Labs, California Ag Labs) with published Certificates of Analysis. The company operates exclusively through licensed medical clinics via a HIPAA-compliant Provider Portal that offers ordering systems, clinical training, and support resources. Pico IV's products are currently available in over 200 clinics across nearly all 50 US states.

Differentiator

Problem solved

Functional benefit

Products and services

  • PICO IV Sterile CBD IV Solution World's first and only sterile CBD IV solution, utilizing proprietary pico-emulsion technology that reduces CBD particles to picometer scale for water solubility and sterile filtration, enabling direct IV administration of CBD for enhanced bioavailability. Sold to licensed medical clinics and wellness providers for in-clinic IV administration.
  • PICO IV CBD Broad Spectrum Vial Sterile CBD IV solution available in 5ml, 10ml, 20ml, and 50ml vials with varying CBD concentrations (approximately 6.4 mg/mL potency). Contains multiple cannabinoids including CBD, CBG, CBGa, CBDa, CBC, and CBN. Third-party lab tested for pesticides, microbials, mycotoxins, heavy metals, and residual solvents.
  • PICO IV Core-A Specialized CBD IV formulation featuring CBD-A and CBG-A acidic cannabinoids at 0.161 mg/mL potency in 5.8ml vials. Third-party lab tested for purity and potency.
  • PICO IV Provider Portal HIPAA-compliant B2B platform providing licensed medical clinics access to ordering, inventory management, clinical resources, training materials, and Certificate of Analysis documentation. Includes 1-on-1 training, FAQs, forum groups, and downloads. Required applicants to be licensed medical clinics.
  • PICO IV Subscriptions (Subscribe & Save) Recurring subscription program offering 20% savings on repeat orders of PICO IV sterile CBD IV vials for registered clinic and consumer members via the picoiv.com storefront.

Quantifiable outcome

  • Available in over 200 clinics across almost all 50 states
  • +1 more outcomes

Companies that use Pico IV

Customer profile

Named customers4 records

Segments3 records

Ideal customer profiles4 records

Pico IV technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration4 records

Feature4 records

Pico IV partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core.

  • BrainThrive, PCcoreStrategic or Co-development Partner · 13 January 2026Clinical collaboration to deliver patented sterile CBD solution at BrainThrive's Westlake Village neurology clinic. Creates a neurologist-guided protocol for CBD IV therapy with structured delivery and real-world clinical measurement using AdvancedMD to document patient-reported outcomes alongside neurological indicators. Aligned with December 19 Executive Order on medical marijuana and CBD research priorities.
  • The DRIPBaRcoreChannel Partner/ Reseller/ Distributor · 4 November 2025Strategic partnership to expand access to sterile CBD solutions nationwide through DRIPBaR's franchise locations. The partnership aims to improve wellness support through IV therapy and CBD products, leveraging both companies' reputations and safety standards. Products accessible via franchise's more than 120 locations.
  • LiquividacoreStrategic or Co-development Partner · 17 September 2025Partnership to bring first sterile CBD emulsion to mainstream wellness protocols. Liquivida founder Sam Tejada joins PICO IV's Advisory Board as official spokesperson while continuing as Chairman of Leadership Advisory Board for American IV Association. Companies plan to educate providers and patients on endocannabinoid system and integrate pharmaceutical-grade CBD (manufactured in cGMP facility using e-beam sterilization) into customized wellness and performance protocols.
  • iCRYOcoreChannel Partner/ Reseller/ Distributor · 5 February 2025Partnership to accelerate availability of CBD IV infusions through iCRYO's national wellness provider network. Pico IV's first-of-its-kind CBD IV therapy (launched August 2023) made available through iCRYO's 50 franchise locations across US and Canada, aiming to accelerate CBD acceptance into mainstream wellness services.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Pico IV competitors and assessment

Company assessment

Direct peers

  • Medterra: CBD brand focused on tinctures, capsules, topicals, and sleep/recovery products, including partnerships with healthcare professionals. Comparable positioning as a science-forward, professionally distributed CBD brand targeting practitioner channels.
  • CBDistillery: Large-scale CBD brand under Balanced Health Botanicals offering tinctures, gummies, capsules, and topicals with strong value positioning. Comparable as a high-volume CBD brand competing for the same practitioner and consumer audience.
  • Elixinol: Global CBD brand (formerly Elixinol Global) producing tinctures, capsules, topicals, and skincare. Comparable as a science-positioned CBD consumer brand with international distribution ambitions.
  • Receptra Naturals: CBD brand focused on recovery, sleep, and active-lifestyle SKUs, with professional/athlete channels. Comparable as a specialty CBD brand targeting wellness, recovery, and practitioner-oriented distribution.
  • cbdMD: Public CBD brand selling tinctures, gummies, topicals, and sleep/recovery products with national retail and DTC reach. Comparable as a multi-format, mass-distributed CBD brand competing for the same wellness-conscious consumer.
  • Lazarus Naturals: Vertically integrated CBD brand offering tinctures, capsules, topicals, and pet products with a strong value and accessibility positioning. Comparable as a multi-format CBD consumer brand with significant scale and broad distribution.
  • Restore Hyper Wellness: National franchise chain offering IV therapy, cryotherapy, infrared, and wellness services — closely matching Pico IV's IV therapy clinic channel. Comparable as a distributed IV therapy operator that could similarly partner with or compete for sterile CBD IV suppliers.

Emerging players

  • Trokie: Smaller CBD pharma-adjacent brand focused on buccal/sublingual CBD delivery with a clinical/pharmacy distribution angle. Comparable as an emerging, clinically-positioned CBD player with a differentiated delivery format similar in spirit to Pico IV's novel IV route.

Broad incumbents

  • Charlotte's Web Holdings: One of the largest and most established CBD wellness brands in the US, selling tinctures, gummies, capsules, and topicals across retail and DTC channels. Comparable as a premium CBD consumer brand, though it lacks Pico IV's sterile IV formulation and B2B clinic channel.
  • CV Sciences (PlusCBD Oil): Public CBD company (PlusCBD Oil brand) producing CBD extracts, capsules, topicals, and pet products. Comparable as a regulated, quality-focused CBD manufacturer operating in similar wellness and practitioner channels.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Pico IV social profiles

Digital presence

Pico IV compliance and trust

Trust signal

Compliance2 records

Pico IV financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Pico IV leadership team

Management profile

Number of profiles

Pico IV funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Pico IV M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pico IV

What does Pico IV do?

Pico IV develops, manufactures, and distributes the world's first sterile CBD IV solution using proprietary pico-emulsion technology that reduces CBD particles to picometer scale (1000x smaller than nanoemulsions), enabling water solubility and passage through sterile filtration for true IV-administerable CBD. The company sells sterile CBD Broad Spectrum Vials (in 5ml, 10ml, 20ml, and 50ml sizes) and a Core-A acidic cannabinoid formulation to licensed medical clinics, wellness franchises, and consumers through a HIPAA-compliant B2B Provider Portal and DTC e-commerce.

Is Pico IV a public or private company?

Pico IV is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Pico IV founded?

Pico IV was founded in 2023. It employs 11 to 50 people.

Where is Pico IV based?

Pico IV is headquartered in Sacramento, United States, in the North America region.

How does Pico IV make money?

Two revenue lines are on record. Sterile CBD IV Product Sales are the primary driver. The others are B2B Provider Portal.

Who are Pico IV's main competitors?

Direct peers on record are Medterra, CBDistillery, Elixinol, Receptra Naturals, cbdMD, Lazarus Naturals and Restore Hyper Wellness. Trokie is listed as an emerging player. Broad incumbents are Charlotte's Web Holdings and CV Sciences (PlusCBD Oil).

Does Pico IV have an API?

No public API is recorded for Pico IV.

What industry is Pico IV in?

Pico IV's product category is Sterile CBD IV Pharmaceutical Products. Its primary akta.pro industry code is HLAFALAE, Compounding Pharmacies (Sterile/Non-Sterile), with a secondary code of CRAOAIAG, Hemp & CBD Product Wholesale Distribution. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireWhy a Neurology Clinic in Los Angeles Is Becoming a Clinical Home for CBD IV TherapyPICO IV announced a clinical collaboration with BrainThrive, PC to deliver its patented sterile CBD solution at BrainThrive's Westlake Village neurology clinic, creating a neurologist-guided protocol for CBD IV therapy with structured delivery and real-world clinical measurement. The partnership aligns with a December 19 Executive Order directing federal agencies to prioritize real-world evidence for medical marijuana and CBD research, with both companies using AdvancedMD to document patient-reported outcomes alongside neurological indicators. The program is currently active at BrainThrive's Westlake Village location as part of an ongoing clinical initiative focused on measuring nervous-system patterns under sustained cognitive and sensory demand.EIN PresswireThe DRIPBaR and PICO IV Partner Together to Expand Access to CBD NationallyPICO IV announced a strategic partnership with The DRIPBaR to offer PICO IV's sterile CBD solution at participating DRIPBaR locations across the United States. PICO IV, which created the world's first sterile CBD solution using patent-pending technology and FDA-approved filtration standards, will leverage The DRIPBaR's network of over 120 franchise locations to expand national access to CBD wellness products. Both companies characterize this collaboration as an opportunity to advance the standard of care in IV therapy and provide science-driven wellness options to a broader customer base.EIN PresswirePICO IV Announces Partnership with The DRIPBaR to Expand CBD Access NationwidePICO IV announced a strategic partnership with The DRIPBaR to distribute its sterile CBD products through The DRIPBaR's network of IV therapy franchise locations nationwide. The partnership will introduce PICO IV's flagship CBD solution across select DRIPBaR locations as part of a phased rollout, with availability varying by clinic and regional compliance guidelines. Both companies described the collaboration as a step forward for expanding access to science-driven wellness products in the IV therapy space.PharmatechnewsA New Era in IV Wellness: Liquivida and PICO IV Are Leading the Movement to Revolutionize Cannabinoid TherapyLiquivida, a nationwide IV therapy provider, has announced a partnership with PICO IV to bring the first sterile CBD emulsion to mainstream wellness protocols. As part of the collaboration, Liquivida founder Sam Tejada will join PICO IV's Advisory Board as its official spokesperson while continuing his role as Chairman of the Leadership Advisory Board for the American IV Association. The companies plan to educate providers and patients on the endocannabinoid system and integrate this pharmaceutical-grade CBD solution, manufactured in a cGMP facility using e-beam sterilization, into customized wellness and performance protocols.PR NewswirePICO IV Announces Strategic Partnership with Liquivida, Names Sam Tejada as SpokespersonPICO IV, the developers of the world's first sterile CBD emulsion, has announced a strategic partnership with Liquivida, a national IV therapy and wellness company, appointing Liquivida founder Sam Tejada to PICO IV's Advisory Board and naming him as brand spokesperson. The partnership aims to expand education around the endocannabinoid system and integrate PICO IV's sterile CBD technology into Liquivida's nationwide network of affiliate clinics and wellness providers. Both companies positioned this collaboration as a pivotal step toward bridging natural medicine and clinical science in the growing wellness market.MorningstarPICO IV Announces Strategic Partnership with Liquivida, Names Sam Tejada as SpokespersonPICO IV announced a strategic partnership with Liquivida, appointing Sam Tejada to its advisory board and spokesperson. The collaboration aims to increase provider awareness of the endocannabinoid system and integrate PICO IV's sterile CBD into clinical protocols. PICO IV's technology claims nearly 100% bioavailability.YahooPICO IV Announces Strategic Partnership with Liquivida, Names Sam Tejada as SpokespersonPICO IV, the developer of the world's first sterile CBD emulsion, has announced a strategic partnership with Liquivida, a national wellness and IV therapy company. As part of the agreement, Liquivida founder Sam Tejada has been appointed to the PICO IV Advisory Board and will serve as spokesperson to promote clinical applications of sterile CBD and educate providers about the endocannabinoid system. The partnership leverages Liquivida's nationwide network of affiliate doctors to expand access to PICO IV's products within clinical and wellness settings.